Pfizer says its Phase 3 clinical trial confirmed COVID-19 vaccine protection lasts at least six months after the second dose and covers emerging variants.
Originally, the company could only guarantee 90 days of protection for vaccinated patients, making six months of protection the best estimate offered to date, according to a Pfizer/BioNTech readout.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.